Phase Ia/Ib dose-escalation study of the anti-TIGIT  tiragolumab as a single agent and in combination with atezolizumab in advanced solid tumors - Johanna C Bendell #AACR20 $RHHBY $MRK $RCUS $MREO $SGEN 4/x

safety, no Gr5 TR, irAEs https://t.co/cyPTC1gYyb